Acadian Asset Management’s UroGen Pharma URGN Stock Holding History

Acadian Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$297K	Buy	+8,113	New	+$220K	﹤0.01%	1567
2023 Q4	–	Sell	-4,563	Closed	-$63K	–	1829
2023 Q3	$63K	Sell	4,563 -2,624	-37%	-$42.1K	﹤0.01%	1398
2023 Q2	$74K	Buy	7,187 +2,624	+58%	+$28.9K	﹤0.01%	1464
2023 Q1	$42K	Buy	+4,563	New	+$42K	﹤0.01%	1542
2018 Q2	–	Sell	-5,315	Closed	-$264K	–	1849
2018 Q1	$264K	Sell	5,315 -18,425	-78%	-$923K	﹤0.01%	1000
2017 Q4	$884K	Sell	23,740 -853	-3%	-$30.4K	﹤0.01%	712
2017 Q3	$775K	Buy	+24,593	New	+$543K	﹤0.01%	724

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Acadian Asset Management's URGN Position: Q2 2026 in Review

Acadian Asset Management opened a new position in UroGen Pharma (URGN) in Q2 2026: 8,113 shares worth $297K. The stake represents ﹤0.01% of the portfolio and ranks #1567 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in URGN as recently as Q3 2023.

Acadian Asset Management first reported a position in URGN in Q3 2017 and has held it in 7 quarters since. The position peaked at $884K in Q4 2017. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Acadian Asset Management held 8,113 shares of UroGen Pharma worth $297K as of Q2 2026.
UroGen Pharma was a new Acadian Asset Management position in Q2 2026.
UroGen Pharma made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1567 holding.
Acadian Asset Management first reported a position in UroGen Pharma in Q3 2017 and has held it in 7 quarters since.
Acadian Asset Management's UroGen Pharma position peaked at $884K in Q4 2017.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.